AnalyzeDirect

Challapalli A, Barwick T, Tomasi G, M OD, Contractor K, Stewart S, Al-Nahhas A, Behan K, Coombes C, Aboagye EO, Mangar S. Exploring the potential of [¹¹C]choline-PET/CT as a novel imaging biomarker for predicting early treatment response in prostate cancer. Nucl Med Commun. January 2014;35(1):20-29.

Publication Date
January 2014

How Analyze was Used
“PET data were analysed using Analyze software (… Overland Park, Kansas, USA).”

Keywords
Androgens/deficiency
Carbon Radioisotopes/diagnostic use
Choline/diagnostic use
Humans
Male
Multimodal Imaging
Neoadjuvant Therapy
Positron-Emission Tomography (PET)
Prostate-Specific Antigen/metabolism
Prostatic Neoplasms/diagnosis/metabolism/therapy
Time Factors
Tomography, X-Ray Computed
Treatment Outcome

Author Affiliation(s)
Departments of Surgery and Cancer Radiology/Nuclear Medicine, Imperial College London and Imperial College Healthcare NHS Trust, The PET Imaging Centre, St Thomas’ Hospital, London, UK.

ID# 82

Tags: Androgens/deficiency, Carbon Radioisotopes/diagnostic use, Choline/diagnostic use, Humans, Male, Multimodal Imaging, Neoadjuvant Therapy, Positron Emission Tomography (PET), Prostate-Specific Antigen/metabolism, Prostatic Neoplasms/diagnosis/metabolism/therapy, Time Factors, Treatment Outcome, X-Ray Computed Tomography